SCHEDULE: 5AM Ventures Reduces Stake in Rallybio Corp
Schedule 13D Amendment
Venture capital firm 5AM Ventures has disclosed the sale of approximately 291,788 shares of Rallybio Corp common stock.
Summary
- 5AM Ventures V, L.P. and 5AM Opportunities I, L.P. have reduced their holdings in Rallybio Corp.
- On May 4, 2026, 5AM Ventures V, L.P. sold 135,319 shares at a weighted average price of $13.95.
- On May 4, 2026, 5AM Opportunities I, L.P. sold 156,469 shares at a weighted average price of $13.95.
- The reporting persons now report 0% beneficial ownership of the issuer's common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event; it is a routine portfolio adjustment by a venture capital firm rather than a reflection of fundamental changes in the issuer's business.
Positives
- The divestment indicates liquidity realization for the venture capital investors.
Negatives
- The exit of a significant venture capital investor may be perceived as a lack of long-term confidence in the issuer's immediate growth prospects.
Risks
- Market volatility associated with the sale of a large block of shares.
Future Outlook
The filing does not provide forward-looking guidance regarding the issuer's business operations, as it is a disclosure of changes in beneficial ownership by an institutional investor.
Industry Context
StockSavvy.ai notes that venture capital firms typically exit positions in biotech companies after reaching specific maturity milestones or fund lifecycle requirements. This divestment is consistent with standard portfolio management practices for venture capital firms.
Comparison to Industry Standards
- The exit of venture capital firms post-IPO or after significant holding periods is a standard industry practice.
- The sale price of $13.95 reflects the market valuation of the issuer at the time of the transaction.
Stakeholder Impact
- Shareholders may experience short-term price pressure due to the increased supply of shares in the market.
Next Steps
- No further actions or milestones are mentioned for the reporting persons.
Key Dates
| Date | Description |
|---|---|
| 08/12/2021 | Original Schedule 13D filing date. |
| 06/07/2022 | Amendment No. 1 filing date. |
| 02/27/2026 | Amendment No. 2 filing date. |
| 05/04/2026 | Date of open market share sales. |
| 05/06/2026 | Filing date of Amendment No. 3. |
Keywords
Rallybio, 5AM Ventures, Schedule 13D, Divestment, Biotech, Insider Selling
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.